OWKIN Company Profile

09:51 EDT 23rd June 2018 | BioPortfolio

OWKIN is a predictive analytics company that utilizes transfer learning to accelerate drug discovery and development. OWKIN’s proprietary platform, OWKIN Plus uses machine learning-based modeling to analyze molecular, imaging libraries and patient datasets to uncover complex biomarker patterns that cause disease. OWKIN partners with leading pharmaceutical companies including Amgen and Actelion and the Company has programs in development with Institut Curie, Centre Leon Berard and Saint Louis Hospital. For more information, visit and follow @OWKINscience on Twitter.

News Articles [8 Associated News Articles listed on BioPortfolio]

A.I. for Healthcare Gets Even More Crowded as GV Invests in Owkin

More money continues to flow into startups seeking to harness the massive amount of data available in healthcare using artificial intelligence and machine learning. This time, GV, the venture capital ...

OWKIN CEO Outlines AI's 'Transfer Learning' Promise In Drug Discovery

Privately owned startup OWKIN will use $11m raised in a Series A funding for new hires and building its predictive...    

OWKIN secures $11m to scale AI-driven drug discovery platform

The predictive analytics company OWKIN uses a new AI technique called transfer learning to accelerate drug discovery and development.

$11M Round for AI Algorithms to Speed up Drug Development

Owkin has raised $11M in a Series A round to fund its artificial intelligence platform for medical research and drug discovery.  Owkin, based in New York and Paris, was founded in 2016 to develop mac...

Owkin raises $11M in series A

OWKIN Closes $11 Million Series A Financing Round

- Otium Venture leads Series A round with participation from Cathay Innovation, Plug and Play and NJF Capital - Funding will expand OWKIN Socrates, the first data driven ...

Which Biotechs Enjoyed A 'JPM Jump' - And Which Lost Out?

As participants from this year’s J.P. Morgan Healthcare conference recover from the torrent of new information they were exposed to...   

Astellas' ASP0113 Trial Failure Gives Merck's Prevymis Further CMV Boost

Merck's Prevymis should benefit from the failure of ASP0113 in a late-stage trial treating cytomegalovirus in certain kidney transplant patients.   

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [1 Associated Companies listed on BioPortfolio]


OWKIN is a predictive analytics company that utilizes transfer learning to accelerate drug discovery and development. OWKIN’s proprietary platform, OWKIN Plus uses machine le...

More Information about "OWKIN" on BioPortfolio

We have published hundreds of OWKIN news stories on BioPortfolio along with dozens of OWKIN Clinical Trials and PubMed Articles about OWKIN for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of OWKIN Companies in our database. You can also find out about relevant OWKIN Drugs and Medications on this site too.

Quick Search


Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Corporate Database Quicklinks

Searches Linking to this Company Record